货号:A120381 同义名: 达格列嗪 / BMS-512148
Dapagliflozin(BMS-512148)是一种治疗糖尿病的新药,是一种竞争性钠/葡萄糖协同转运蛋白2(SGLT2)抑制剂,导致尿中葡萄糖排泄。Dapagliflozin诱导HIF1表达并减少肾缺血再灌注损伤。
There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type | HazMat fee for 500 gram (Estimated) |
Excepted Quantity | USD 0.00 |
Limited Quantity | USD 15-60 |
Inaccessible (Haz class 6.1), Domestic | USD 80+ |
Inaccessible (Haz class 6.1), International | USD 150+ |
Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10mM*1mL(DMSO) | ¥660 | 咨询 | |
5mg | ¥600 | 咨询 | |
10mg | ¥880 | 咨询 | |
50mg | ¥2200 | 咨询 | |
100mg | ¥3600 | 咨询 | |
1g | ¥22040 | 咨询 |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | SGLT1 ↓ ↑ | SGLT2 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Phloretin | ✔ | 98% | |||||||||||||||||
Canagliflozin |
+++
hSGLT2, IC50: 3.7 nM mSGLT2, IC50: 2 nM | 95% | |||||||||||||||||
Empagliflozin |
++
SGLT2, IC50: 3.1 nM | 98% | |||||||||||||||||
Dapagliflozin |
++++
hSGLT2, EC50: 1.1 nM | 97% | |||||||||||||||||
Tofogliflozin (hydrate) |
+++
hSGLT2, IC50: 2.9 nM | 99%+ | |||||||||||||||||
Sotagliflozin |
+
SGLT1, IC50: 36 nM |
++++
SGLT2, IC50: 1.8 nM | 98% | ||||||||||||||||
Ipragliflozin |
++
hSGLT2, IC50: 7.4 nM | 98% | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
靶点 |
|
描述 | The sodium-dependent glucose transport (SGLT) proteins belong to the sodium glucose cotransporter family. Sodium-dependent glucose transport 2 (SGLT2) is a high-capacity, low-affinity transporter that is expressed mainly in the kidney. It has a Na(+) to glucose coupling ratio of 1:1. It is estimated that 90% of renal glucose reabsorption is facilitated by SGLT2 residing on the surface of the epithelial cells lining the S1 segment of the proximal tubule. Dapagliflozin is a potent and selective SGLT2 inhibitor. In an experiment system of Chinese hamster ovary cells stably expressing human SGLT2 and SGLT1, data yielded by monitoring inhibition of AMG showed that the EC50 of dapagliflozin for human SGLT2 inhibition was 1.1 nM, while that for human SGLT1 was 1390 nM[7]. In acute normal and diabetic rat studies, SD or ZDF rats were dosed orally with single doses of dapagliflozin at 0.01 mg/kg, 0.1 mg.kg, 1 mg/kg or 10 mg/kg. In normal rats, the results were that dapagliflozin caused significant dose-dependent glucosuria and increase in urine volume, with 1 mg/kg producing a 400-fold increase in urine glucose and a threefold increase in urine volume versus vehicle over 24 h post-dose. Dapagliflozin administration was also associated with a reduction in glucose area under the curve over 1 h post-dose at 1 and 10 mg/kg doses in the glucose tolerance test in normal rats. In ZDF rats, dapagliflozin dose-dependently increased urine glucose and urine volume excretion at 6 h post-dose [8]. In another study, dapagliflozin was administrated at the dose of 0.5 mg/kg orally once daily for 15 days. When measured 24 h after the final dose on day 15, ZDF rats treated with dapagliflozin displayed a 53% decrease in 18-h FPG level compared with vehicle-treated rats[8]. |
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
CHO cells | Function assay | 2 h | Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting, IC50=0.00049 μM | 20434909 | |
CHOK1 cells | Function assay | 3 h | Inhibition of human SGLT2 expressed in CHOK1 cells assessed as inhibition of [14C]-AMG uptake after 3 hrs by microbeta scintillation counting analysis, IC50=0.001 μM | 24842618 | |
COS-7 cells | Function assay | 2 h | Inhibition of human SGLT1 transfected in COS-7 cells assessed as AMG uptake after 2 hrs by scintillation counting, IC50=0.89 μM | 19896374 | |
HEK293.ETN cells | Function assay | 1.5 h | Inhibition of human SGLT2 transfected in HEK293.ETN cells assessed as AMG uptake after 1.5 hrs by scintillation counting, IC50=0.0067 μM | 19896374 | |
Dose | Rat: 0.1 mg/kg - 1 mg/kg[3] (p.o.); 10 mg/kg[4] (i.p.), 75 mg/kg, 150 mg/kg[5] (i.p.) | ||||||||||||||||||
Administration | p.o., i.p. | ||||||||||||||||||
Pharmacokinetics |
|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02096705 | Diabetes | Phase 3 | Completed | - | - |
NCT03565458 | Type 2 Diabetes Mellitus | Phase 1 | Active, not recruiting | December 22, 2018 | Korea, Republic of ... 展开 >> LG chem Seoul, Gangseo-Gu, Korea, Republic of, 07795 收起 << |
NCT02096705 | - | Completed | - | - | |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM | 2.45mL 0.49mL 0.24mL | 12.23mL 2.45mL 1.22mL | 24.46mL 4.89mL 2.45mL |
CAS号 | 461432-26-8 |
分子式 | C21H25ClO6 |
分子量 | 408.87 |
别名 | 达格列嗪 ;BMS-512148 |
运输 | 蓝冰 |
存储条件 | 液体 -20°C:3-6个月-80°C:12个月 粉末 Sealed in dry,2-8°C |
溶解度 | DMSO: 105 mg/mL(256.81 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 50 mg/mL(122.29 mM),配合低频超声助溶 |
动物实验配方 | IP 2% DMSO+2% Tween80+40% PEG300+water 2.4 mg/mL clear PO 0.5% CMC-Na 16 mg/mL suspension |
Tags: Dapagliflozin | BMS-512148 | 达格列嗪 | Sugar Alcohol | SGLT | AmBeed-信号通路专用抑制剂 | Dapagliflozin 纯度/质量文件 | Dapagliflozin 亚型比较 | Dapagliflozin 生物活性 | Dapagliflozin 细胞研究 | Dapagliflozin 动物研究 | Dapagliflozin 临床数据 | Dapagliflozin 参考文献 | Dapagliflozin 实验方案 | Dapagliflozin 技术信息
请填写此表格索取QC报告。我们很快就会发送到您的邮箱。您的信息在我们这里是安全的。*是必填项.
靶点 | 数值 |
SGLT2 |
hSGLT2, EC50:1.1 nM |
需要的总药量: mg
您需要配制的工作液浓度为:mg/mL
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
CHO cells | Function assay | 2 h | Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting, IC50=0.00049 μM | 20434909 | |
CHOK1 cells | Function assay | 3 h | Inhibition of human SGLT2 expressed in CHOK1 cells assessed as inhibition of [14C]-AMG uptake after 3 hrs by microbeta scintillation counting analysis, IC50=0.001 μM | 24842618 | |
COS-7 cells | Function assay | 2 h | Inhibition of human SGLT1 transfected in COS-7 cells assessed as AMG uptake after 2 hrs by scintillation counting, IC50=0.89 μM | 19896374 | |
HEK293.ETN cells | Function assay | 1.5 h | Inhibition of human SGLT2 transfected in HEK293.ETN cells assessed as AMG uptake after 1.5 hrs by scintillation counting, IC50=0.0067 μM | 19896374 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02096705 | Diabetes | Phase 3 | Completed | - | - |
NCT03565458 | Type 2 Diabetes Mellitus | Phase 1 | Active, not recruiting | December 22, 2018 | Korea, Republic of ... 展开 >> LG chem Seoul, Gangseo-Gu, Korea, Republic of, 07795 收起 << |
NCT02096705 | - | Completed | - | - | |
NCT00831779 | Type 2 Diabetes Mellitus | Phase 2 | Completed | - | United States, California ... 展开 >> Va San Diego Healthcare System San Diego, California, United States, 92161 United States, Louisiana Pennington Biomedical Research Center Baton Rouge, Louisiana, United States, 70808 United States, Pennsylvania Temple University General Clinical Research Center Philadelphia, Pennsylvania, United States, 19140 收起 << |
NCT02419612 | - | Active, not recruiting | - | - | |
NCT00831779 | - | Completed | - | - | |
NCT02419612 | Diabetes | Phase 3 | Active, not recruiting | August 15, 2019 | - |
NCT03419624 | Obesity Diabe... 展开 >>tes Mellitus, Type 2 收起 << | Phase 3 | Recruiting | June 15, 2019 | Germany ... 展开 >> Diabeteszentrum Oldenburg Recruiting Oldenburg, Lower Saxony, Germany, 23758 Contact: Thomas Schaum, MD +494361513622 info@diabeteszentrum-oldenburg.de Principal Investigator: Thomas Schaum, MD University Medical Center Hamburg-Eppendorf Recruiting Hamburg, Germany, 20246 Contact: Anne Lautenbach, MD +4915222816188 a.lautenbach@uke.de Contact: Hilko TD Wittmann h.wittmann@uke.de Diabetologische Schwerpunktpraxis Harburg Recruiting Hamburg, Germany, 21073 Contact: Bjoern Paschen, MD +4940557753300 info@diabetologie-harburg.de Principal Investigator: Bjoern Paschen, MD Gemeinschaftspraxis für Innere Medizin und Diabetologie Recruiting Hamburg, Germany, 22607 Contact: Dominik Dahl, MD +4940896295 Principal Investigator: Dominik Dahl, MD 收起 << |
NCT02471404 | Type 2 Diabetes Mellitus ... 展开 >> Inadequate Glycaemic Control 收起 << | Phase 4 | Completed | - | - |
NCT01137474 | - | Completed | - | - | |
NCT01137474 | Type 2 Diabetes | Phase 3 | Completed | - | - |
NCT00736879 | Type 2 Diabetes Mellitus | Phase 3 | Completed | - | - |
NCT01525238 | - | Completed | - | - | |
NCT01525238 | Type 2 Diabetes Mellitus | Phase 1 | Completed | - | United States, Alabama ... 展开 >> The Children Hospital Of Alabama Birmingham, Alabama, United States, 35233 United States, California Axis Clinical Trials Los Angeles, California, United States, 90036 United States, Florida Nemours Childrens Hospital Orlando, Florida, United States, 32827 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Kentucky Kosair Charities Pediatric Clinical Research Unit Louisville, Kentucky, United States, 40202 United States, Louisiana Lsuhsc-Shreveport Shreveport, Louisiana, United States, 71103 United States, Missouri Childrens Mercy Hospital Kansas City, Missouri, United States, 64108 United States, New York Women And Children'S Hopsital Of Buffalo Buffalo, New York, United States, 14222 United States, Ohio Promedica Toledo Children'S Hospital Toledo, Ohio, United States, 43606 Mercy Children'S Hospital Toledo, Ohio, United States, 43608 United States, Pennsylvania Children'S Hospital Of Philadelphia Philadelphia, Pennsylvania, United States, 19104 Children'S Hospital Of Pittsburgh Of Upmc Pittsburgh, Pennsylvania, United States, 15224 United States, Tennessee Methodist Le Bonheur Hlthcare Memphis, Tennessee, United States, 38103 United States, Texas Christus Santa Rosa Childrens Hospital San Antonio, Texas, United States, 78207 Mexico Local Institution Guadalajara, Jalisco, Mexico, 44150 Local Institution Monterrey, Nuevo Leon, Mexico, 64460 Local Institution Veracruz, Mexico, 91910 收起 << |
NCT00736879 | - | Completed | - | - | |
NCT02520518 | Weight Loss | Phase 2 | Terminated(Designed a new modi... 展开 >>fied/simplified protocol see NCT 03180489) 收起 << | - | United States, Colorado ... 展开 >> Colorado State University, Dept. of Health and Exercise Science Fort Collins, Colorado, United States, 80523-1582 收起 << |
NCT00930865 | Type 2 Diabetes Mellitus | Phase 1 | Completed | - | United States, Texas ... 展开 >> Ppd Development, Lp Austin, Texas, United States, 78744 收起 << |
NCT02520518 | - | Terminated(Designed a new modi... 展开 >>fied/simplified protocol see NCT 03180489) 收起 << | - | - | |
NCT01072578 | Healthy Volunteers | Phase 1 | Completed | - | Germany ... 展开 >> Research Site Berlin, Germany 收起 << |
NCT02551874 | Type 2 Diabetes Mellitus | Phase 3 | Completed | - | - |
NCT03007329 | Steatosis, Liver ... 展开 >> Type2 Diabetes 收起 << | Phase 4 | Recruiting | January 2019 | Austria ... 展开 >> Abt. für Endokrinologie & Stoffwechsel, Univ. Klin f. Innere Medizin III Recruiting Wien, Austria, 1090 Contact: Magdalena Bastian, BSc Contact: Jürgen Harreiter, MD juergen.harreiter@meduniwien.ac.at 收起 << |
NCT02551874 | - | Completed | - | - | |
NCT02229396 | Diabetes Mellitus | Phase 3 | Completed | - | - |
NCT03710460 | Obesity | Phase 4 | Recruiting | June 30, 2019 | Mexico ... 展开 >> Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara Recruiting Guadalajara, Jalisco, Mexico, 44340 Contact: Manuel Gonzalez, PhD +52-10-58-52-00 ext 34212 uiec@prodigy.net.mx Contact: Esperanza Martinez, PhD +52-10-58-52-00 ext 34212 esperanzamartnezabundi@yahoo.com 收起 << |
NCT02229396 | - | Completed | - | - | |
NCT01055652 | Type 2 Diabetes Mellitus | Phase 1 | Completed | - | Japan ... 展开 >> Research Site Moriya, Japan Research Site Osaka, Japan 收起 << |
NCT02433678 | Type 2 Diabetes | Phase 4 | Unknown | May 2018 | United States, New York ... 展开 >> ECMC Ambulatory Center, 3rd Floor Recruiting Buffalo, New York, United States, 14215 Contact: Paresh Dandona, MD 716-898-1940 pdandona@kaleidahealth.org Contact: Jeanne Hejna, LPN 716-898-1944 jeannehe@buffalo.edu 收起 << |
NCT02235298 | Type 2 Diabetes | Phase 4 | Recruiting | December 2019 | United States, Florida ... 展开 >> University of Miami Recruiting Miami, Florida, United States, 33136 Contact: Gianluca Iacobellis, MD PhD giacobellis@med.miami.edu Principal Investigator: Gianluca Iacobellis, MD PhD University of Miami Recruiting Miami, Florida, United States, 33136 Contact: Gianluca Iacobellis, MD PhD giacobellis@med.miami.edu 收起 << |
NCT02751398 | Type 2 Diabetes Mellitus | Phase 4 | Unknown | December 2017 | Korea, Republic of ... 展开 >> Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine Recruiting Seoul, Korea, Republic of, 120-752 Contact: Geu-Ru Hong, MD, PhD 82-2-2228-8443 GRHONG@yuhs.ac 收起 << |
NCT03193684 | Hepatic Glucose Metabolism | Phase 4 | Recruiting | January 31, 2023 | United States, Texas ... 展开 >> Diabetes Division, UTHSCSA Recruiting San Antonio, Texas, United States, 78229 Contact: Andrea Hansis-Diarte, MPH 210-617-5300 ext 17822 HansisDiarte@uthscsa.edu 收起 << |
NCT01392677 | Type 2 Diabetes Mellitus ... 展开 >> High HbA1c Level Inadequate Glycaemic Control 收起 << | Phase 3 | Completed | - | - |
NCT02811484 | Diabetes Mellitus, Type 2 | Phase 4 | Withdrawn(Inability to enroll ... 展开 >>due to the widespread use of both classes of drugs in patients with T2DM, including those on concomitant insulin therapy.) 收起 << | December 2018 | United States, New York ... 展开 >> Comprehensive Weight Control Center New York, New York, United States, 10065 收起 << |
NCT00984867 | Type 2 Diabetes | Phase 3 | Completed | - | - |
NCT02700334 | Prediabetes I... 展开 >>mpaired Fasting Glucose Impaired Glucose Tolerance 收起 << | Phase 4 | Completed | - | Mexico ... 展开 >> Intstituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara Guadalajara, Jalisco, Mexico, 44340 收起 << |
NCT00984867 | - | Completed | - | - | |
NCT03199053 | Diabetes Mellitus, Type 2 | Phase 3 | Recruiting | December 20, 2021 | - |
NCT02268214 | Type 1 Diabetes Mellitus | Phase 3 | Completed | - | - |
NCT01392677 | - | Completed | - | - | |
NCT02268214 | - | Completed | - | - | |
NCT03006471 | PreDiabetes P... 展开 >>rehypertension 收起 << | Phase 4 | Active, not recruiting | December 2018 | Mexico ... 展开 >> Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara Guadalajara, Jalisco, Mexico, 44340 收起 << |
NCT01662999 | Type 2 Diabetes Mellitus | Phase 1 | Completed | - | United States, Nebraska ... 展开 >> Icon Clinical Pharmacology Omaha, Nebraska, United States, 68154 收起 << |
NCT03608358 | Type 2 Diabetes Mellitus | Phase 3 | Not yet recruiting | March 1, 2021 | China ... 展开 >> Research Site Not yet recruiting Baotou, China, 014016 Research Site Not yet recruiting Beijing, China, 100039 Research Site Not yet recruiting Beijing, China, 100044 Research Site Not yet recruiting Beijing, China, 100101 Research Site Not yet recruiting Beijing, China, 100144 Research Site Not yet recruiting Beijing, China, 101199 Research Site Not yet recruiting Beijing, China, 101200 Research Site Not yet recruiting Changchun, China, 130021 Research Site Not yet recruiting Chenzhou, China Research Site Withdrawn Chongqing, China, 400014 Research Site Not yet recruiting Fuzhou, China, 350025 Research Site Withdrawn Guangzhou, China, 510000 Research Site Withdrawn Guangzhou, China, 510080 Research Site Not yet recruiting Guangzhou, China, 510515 Research Site Not yet recruiting Haerbin, China, 150001 Research Site Not yet recruiting Hefei, China, 230001 Research Site Not yet recruiting Hefei, China Research Site Not yet recruiting Hengyang, China, CN-421001 Research Site Not yet recruiting Hohhot, China, 010017 Research Site Not yet recruiting Huizhou, China, 516001 Research Site Not yet recruiting Jinan, China, 250001 Research Site Withdrawn Jinzhou, China, 121004 Research Site Withdrawn Nanchang, China, 330006 Research Site Not yet recruiting Nanjing, China, 210012 Research Site Not yet recruiting Nanjing, China, 210029 Research Site Not yet recruiting Nantong, China, 226001 Research Site Not yet recruiting Qingdao, China, 266003 Research Site Not yet recruiting Shanghai, China, 200240 Research Site Not yet recruiting Shantou, China, 515065 Research Site Not yet recruiting Shengyang, China, 110004 Research Site Not yet recruiting Tangshan, China Research Site Not yet recruiting Tianjin, China, 300211 Research Site Not yet recruiting Wuhan, China, 430033 Research Site Not yet recruiting Wuhan, China, CN-430022 Research Site Not yet recruiting Wulumuqi, China, 830054 Research Site Not yet recruiting Xian, China, 710061 Research Site Withdrawn Xining, China, 810001 Research Site Not yet recruiting Yancheng, China, 224005 Research Site Withdrawn Yinchuan, China, 750004 Research Site Not yet recruiting Yueyang, China, 414000 Research Site Not yet recruiting Zhuzhou, China, 412007 Thailand Research Site Not yet recruiting Bangkok, Thailand, 10400 Vietnam Research Site Not yet recruiting Ho Chi Minh, Vietnam, 10000 Research Site Not yet recruiting Ho Chi Minh, Vietnam 收起 << |
NCT01877889 | Healthy | Phase 1 | Completed | - | Germany ... 展开 >> Neuss, Germany 收起 << |
NCT03592667 | Hypertension | Phase 4 | Enrolling by invitation | May 2019 | Mexico ... 展开 >> Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara Guadalajara, Jalisco, Mexico, 44340 收起 << |
NCT02547935 | Type 2 Diabetes Mellitus, CKD ... 展开 >>and Albuminuria 收起 << | Phase 2 Phase 3 | Completed | - | - |
NCT02965443 | Type 2 Diabetes | Phase 4 | Recruiting | June 2020 | Germany ... 展开 >> University Hospital Tübingen Recruiting Tübingen, Germany, 72076 Contact: Norbert Stefan, Prof. 收起 << |
NCT02681094 | Type 2 Diabetes Mellitus ... 展开 >> Inadequate Glycaemic Control 收起 << | Phase 3 | Completed | - | - |
NCT01165268 | Type 2 Diabetes Mellitus | Phase 1 | Completed | - | United States, California ... 展开 >> Profil Institute For Clinical Research, Inc. Chula Vista, California, United States, 91911 收起 << |
NCT01662999 | - | Completed | - | - | |
NCT03748810 | - | Recruiting | December 31, 2018 | Korea, Republic of ... 展开 >> Chungbuk National University Hospital Recruiting Cheonju, Chungcheongbuk-do, Korea, Republic of, 28644 Contact: Eu Jeong Ku, MD 82-10-3462-8863 eujeong.ku@gmail.com 收起 << | |
NCT02681094 | - | Completed | - | - | |
NCT03714594 | Glucose, Low Blood | Phase 2 | Recruiting | September 2021 | Italy ... 展开 >> Department of Endocrinology and Metabolism, University of Pisa Recruiting Pisa, Italy, 56124 Contact: Stefano Del Prato, MD +39 050 995103 stefano.delprato@med.unipi.it Sub-Investigator: Giuseppe Daniele, MD 收起 << |
NCT02518945 | Type 1 Diabetes Mellitus | Phase 3 | Unknown | - | United States, New York ... 展开 >> ECMC Ambulatory Center, 3rd Floor Recruiting Buffalo, New York, United States, 14215 Contact: Nitesh D Kuhadiya, MD, MPH 716-898-1940 nkuhadiya@gmail.com Contact: Jeanne Hejna, LPN 716-898-1944 jeannehe@buffalo.edu 收起 << |
NCT02610088 | Diabetes | Phase 4 | Completed | - | Korea, Republic of ... 展开 >> Seoul National University Bundang Hospital Seongnam, Gyeonggi, Korea, Republic of, 463-707 收起 << |
NCT02719756 | Diabetes Mellitus ... 展开 >> Hypoglycemic Episodes 收起 << | Phase 4 | Unknown | December 2016 | Russian Federation ... 展开 >> Research Clinical Centre of the Russian Railways, JSC Not yet recruiting Moscow, Russian Federation, 125993 Contact: Alexander Ametov, prof., MD (499)1510951 ext 8107 alexander.ametov@gmail.ru Contact: Viktoria Blagova, PhD cand. (499)6130363 ext 8107 vika-blagova@mail.ru 收起 << |
NCT02113241 | Metabolic Syndrome X | Phase 4 | Completed | - | Mexico ... 展开 >> Intstituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara Guadalajara, Jalisco, Mexico, 44340 收起 << |
NCT03152084 | Diabetes Mellitus, Type 2 ... 展开 >> Kidney Function Tests 收起 << | Phase 4 | Recruiting | July 1, 2019 | Netherlands ... 展开 >> Research Site Recruiting Almelo, Netherlands, 7600 Research Site Recruiting Amsterdam, Netherlands, 1081 HV 收起 << |
NCT02313220 | Obesity | Phase 2 | Completed | - | Sweden ... 展开 >> Dept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University and Section for Diabetes and Endocrinology at the Uppsala University Hospital Uppsala, Sweden, 75185 收起 << |
NCT02719132 | Diabetes Mellitus Type 2 | Phase 4 | Withdrawn | November 2017 | - |
NCT02475070 | Type 2 Diabetes | Phase 4 | Completed | - | Sweden ... 展开 >> Lund University Lund, Sweden, 22184 收起 << |
NCT03331289 | Diabetes Mellitus, Type 2 | Phase 4 | Recruiting | October 30, 2019 | United States, Texas ... 展开 >> University Health System Texas Diabetic Institute Recruiting San Antonio, Texas, United States, 78207 Contact: Ralph DeFronzo, MD 210-567-6691 defronzo@uthscsa.edu 收起 << |
NCT02956811 | Type 2 Diabetes ... 展开 >> Left Ventricular Hypertrophy 收起 << | Phase 4 | Active, not recruiting | March 2019 | United Kingdom ... 展开 >> Ninewells Hospital Dundee, United Kingdom 收起 << |
NCT03313752 | Type2 Diabetes Mellitus ... 展开 >> Stable Coronary Artery Disease 收起 << | Phase 3 | Recruiting | June 2019 | Italy ... 展开 >> Center For Endocrine and Metabolic Diseases - Catholic University Recruiting Rome, RM, Italy, 00168 Contact: ANDREA GIACCARI, MD, PhD +390630156664 andrea.giaccari@unicatt.it Contact: SERENA ROTUNNO +390630158272 serenarotunno@guest.policlinicogemelli.it Principal Investigator: ANDREA GIACCARI, MD, PHD 收起 << |
NCT03387683 | Diabetes Mellitus Type 2 | Phase 4 | Recruiting | April 1, 2019 | Finland ... 展开 >> Research Site Recruiting Turku, Finland, 20520 Sweden Research Site Recruiting Uppsala, Sweden, SE-751 85 收起 << |
NCT02798757 | Diabetes | Phase 4 | Recruiting | May 2018 | Greece ... 展开 >> University of Ioannina Recruiting Ioánnina, Greece, 45500 Contact: Vasilis Tsimihodimos, Assistant Professor +306971705609 vtsimi@uoi.gr 收起 << |
NCT02582840 | Type 1 Diabetes Mellitus | Phase 1 | Completed | - | Japan ... 展开 >> Fukuoka-shi, Japan 收起 << |
NCT01195662 | Type 2 Diabetes | Phase 3 | Completed | - | - |
NCT02725593 | Type 2 Diabetes | Phase 3 | Recruiting | April 24, 2020 | - |
NCT01195662 | - | Completed | - | - | |
NCT02157298 | Type 2 Diabetes Mellitus | Phase 4 | Completed | - | Japan ... 展开 >> Research Site Adachi-ku, Japan Research Site Chitose-shi, Japan Research Site Chiyoda-ku, Japan Research Site Chuo-ku, Japan Research Site Fukuoka-shi, Japan Research Site Hirosaki-shi, Japan Research Site Kamakura-shi, Japan Research Site Koriyama-shi, Japan Research Site Mitaka-shi, Japan Research Site Oita-Shi, Japan Research Site Osaka-shi, Japan Research Site Sendai-shi, Japan Research Site Shizuoka-shi, Japan Research Site Yokohama-shi, Japan 收起 << |
NCT02157298 | - | Completed | - | - | |
NCT03660683 | Diabetes Mellitus, Type 2 ... 展开 >> Cardiovascular Diseases 收起 << | Phase 4 | Recruiting | July 1, 2020 | United States, District of Col... 展开 >>umbia The GW Medical Faculty Associates Recruiting Washington, District of Columbia, United States, 20037 Contact: Hassan Awal, MD hawal@mfa.gwu.edu 收起 << |
NCT03723252 | Nonalcoholic Steatohepatitis | Phase 3 | Not yet recruiting | November 2021 | China, Guangdong ... 展开 >> Nanfang Hospital of Southern Medical University Not yet recruiting Guangzhou, Guangdong, China, 510515 Contact: Huijie Zhang, MD,PhD +86-020-61641635 Huijiezhang2005@126.com Contact: Jinjun Chen, MD,PhD +86-020-62787310 chjj@smu.edu.cn 收起 << |
NCT02420392 | Diabetes Mellitus, Type 2 | Not Applicable | Completed | - | Korea, Republic of ... 展开 >> Seoul National University Hospital Seoul, Korea, Republic of, 110-744 收起 << |
NCT02911792 | Diabetes Mellitus, Type 2 | Phase 4 | Recruiting | April 2019 | United States, Florida ... 展开 >> Sanford Burnham Prebys Medical Discovery Institute Not yet recruiting Orlando, Florida, United States, 32827 Contact: Richard Pratley, MD 407-745-2145 rpratley@SBPdiscovery.org United States, Illinois Northwestern Medical School Not yet recruiting Chicago, Illinois, United States, 60611 Contact: Mark Molitch, MD 312-503-4130 molitch@northwestern.edu The University of Chicago Not yet recruiting Chicago, Illinois, United States, 60637 Contact: George Bakris, MD 773-702-7936 gbakris@medicine.bsd.uchicago.edu United States, Texas The University of Texas Health Science Center at San Antonio Not yet recruiting San Antonio, Texas, United States, 78229 Contact: Ralph A DeFronzo, MD 210-567-6691 defronzo@uthscsa.edu Contact: Monica Palomo, BS 210-567-6710 palomom@uthscsa.edu Sub-Investigator: Ralph A DeFronzo, MD Principal Investigator: Eugenio Cersosimo, MD University Health Systems Texas Diabetic Institute Recruiting San Antonio, Texas, United States Contact: Eugenio Cersosimo, MD 210-358-7200 cersosimo@uthscsa.edu United States, Washington Sacred Heart Medical Center Not yet recruiting Spokane, Washington, United States, 99204 Contact: Katherine Tuttle, MD 509-340-0930 Australia, Victoria Baker Medical Research Institute and Alfred Hospital Not yet recruiting Melbourne, Victoria, Australia Contact: Mark Cooper, MD 61385321362 mark.cooper@bakeridi.edu.au 收起 << |
NCT02460978 | Type 1 Diabetes Mellitus | Phase 3 | Completed | - | - |
NCT03556033 | Diabetes Mellitus, Type 1 ... 展开 >> Hypoglycemia Hypoglycemia Unawareness 收起 << | Phase 2 | Not yet recruiting | December 2019 | Netherlands ... 展开 >> Radboud university medical center Not yet recruiting Nijmegen, Netherlands, 6500HB Contact: L. van Meijel 收起 << |
NCT02459353 | Type 2 Diabetes Mellitus | Phase 4 | Completed | - | Korea, Republic of ... 展开 >> Seoul St.Mary's Hospital Seoul, Korea, Republic of 收起 << |
NCT02962492 | Evaluate Ketogenic Stress | Phase 4 | Unknown | October 2018 | United States, New York ... 展开 >> ECMC Ambulatory Center, 3rd Floor Buffalo, New York, United States, 14215 收起 << |
NCT02460978 | - | Completed | - | - | |
NCT02372955 | Diabetes Mellitus Type 2 | Phase 4 | Unknown | December 2016 | United States, Louisiana ... 展开 >> Gulf Regional Research & Educational Services, LLC Recruiting Metairie, Louisiana, United States, 70002 Contact: Thomas D Giles, MD 504-834-8668 tgiles4@cox.net Contact: Louise E Roffidal, BSN, MPH 504.220.6275 lroffidal.grres@gmail.com 收起 << |
NCT02327039 | Type 2 Diabetes | Phase 4 | Completed | - | Italy ... 展开 >> Division of Metabolic Diseases, University Hospital of Padova Padova, Italy, 35128 收起 << |
NCT02582814 | Type 1 Diabetes Mellitus | Phase 3 | Completed | - | Japan ... 展开 >> Research Site Aizu Wakamatsu-shi, Japan Research Site Chuo-ku, Japan Research Site Fukuoka-shi, Japan Research Site Fukuyama-shi, Japan Research Site Funabashi-shi, Japan Research Site Hamamatsu-shi, Japan Research Site Hirosaki-shi, Japan Research Site Ise-shi, Japan Research Site Kagoshima-shi, Japan Research Site Koriyama-shi, Japan Research Site Kumamoto-shi, Japan Research Site Kunitachi-shi, Japan Research Site Minato-ku, Japan Research Site Nagoya-shi, Japan Research Site Oita-shi, Japan Research Site Otsu-shi, Japan Research Site Oyama-shi, Japan Research Site Sapporo-shi, Japan Research Site Sendai-shi, Japan Research Site Shinjyuku-ku, Japan Research Site Suita-shi, Japan Research Site Tama-shi, Japan Research Site Tsukuba-shi, Japan Research Site Yokohama-shi, Japan 收起 << |
NCT02984644 | Type II; Diabetes | Phase 3 | Recruiting | January 31, 2020 | United States, Texas ... 展开 >> University of Texas Health Science Center Recruiting San Antonio, Texas, United States, 78229 Contact: Eugenio Cersosimo Principal Investigator: Ralph A DeFronzo, MD 收起 << |
NCT03658031 | PreDiabetes M... 展开 >>yocardial Infarction T2DM (Type 2 Diabetes Mellitus) CVD 收起 << | Phase 3 | Not yet recruiting | January 31, 2021 | Qatar ... 展开 >> Heart Hospital, Hamad Medical Coorporation Not yet recruiting Doha, Qatar, 3050 Contact: Jassim Al-Suwaidi, MD 55823041 jalsuwaidi@hotmail.com 收起 << |
NCT03316131 | Asymptomatic Hyperuricemia | Phase 2 | Completed | - | United States, California ... 展开 >> Research Site Glendale, California, United States, 91206 United States, Maryland Research Site Baltimore, Maryland, United States, 21225 收起 << |
NCT02682563 | Diabetes Mellitus, Type 2 ... 展开 >> Diabetic Nephropathies 收起 << | Phase 4 | Completed | - | Netherlands ... 展开 >> VU University Medical Center Amsterdam, Noord-Holland, Netherlands, 1081 HV 收起 << |
NCT03036124 | Chronic Heart Failure With Red... 展开 >>uced Ejection Fraction (HFrEF) 收起 << | Phase 3 | Active, not recruiting | December 4, 2019 | - |
NCT02383238 | Diabetes Mellitus Type 2 | Phase 3 | Completed | - | Germany ... 展开 >> University Erlangen-Nuernberg Erlangen, Germany, 91054 收起 << |
NCT02616666 | Type 2 Diabetes Mellitus | Phase 4 | Recruiting | December 31, 2021 | - |
NCT03704818 | Type1 Diabetes Mellitus | Phase 1 | Recruiting | December 31, 2020 | United States, California ... 展开 >> UC San Diego Altman Clinical & Translational Research Institute Recruiting La Jolla, California, United States, 92037 Contact: Todd May, MS tmay@ucsd.edu 收起 << |
NCT02887677 | Diabetes Mellitus | Phase 4 | Recruiting | December 2019 | Greece ... 展开 >> Ahepa Hospital Recruiting Thessaloniki, Greece, 54621 Contact: Kalliopi Kotsa +306932045201 kalli@med.auth.gr Sub-Investigator: Elena Aggeloudi Hippokrateio Hospital Recruiting Thessaloniki, Greece, 54642 Contact: Asterios Karagiannis +306972011271 astkar@med.auth.gr Sub-Investigator: Eirini Papadopoulou Sub-Investigator: Athanasios Binas Sub-Investigator: Alexia Piperidou Papageorgiou Hospital Recruiting Thessaloniki, Greece, 56429 Contact: Glyceria Tzatzagou 2313323165 tzatzagougl@hotmail.gr Sub-Investigator: Despoina Kosmidou Sub-Investigator: Eleonora Kella 收起 << |
NCT03036150 | Chronic Kidney Disease | Phase 3 | Recruiting | November 27, 2020 | - |
NCT02371187 | Physical Activity | Phase 2 | Completed | - | United States, Colorado ... 展开 >> Colorado State University, Dept. of Health and Exercise Science Fort Collins, Colorado, United States, 80523-1582 收起 << |
NCT01156246 | Healthy | Phase 1 | Completed | - | Sweden ... 展开 >> Research Site Lulea, Sweden 收起 << |
NCT02919345 | Diabetes Mellitus, Type 2 ... 展开 >> Coronary Artery Disease Carotid Artery Diseases 收起 << | Phase 4 | Unknown | October 2017 | Brazil ... 展开 >> State University of Campinas Campinas, Sao Paulo, Brazil, 13083-887 收起 << |
NCT03377335 | Type 2 Diabetes Mellitus | Phase 4 | Active, not recruiting | January 2019 | Italy ... 展开 >> University Hospital of Palermo Palermo, Italy, 90127 收起 << |
NCT02211742 | Fasting Glucose ... 展开 >> Glucose Excursion Glycemic Control 收起 << | Phase 4 | Unknown | November 2015 | Austria ... 展开 >> Medical University Innsbruck, Department of Internal Medicine I Recruiting Innsbruck, Tirol, Austria, 6020 Contact: Markus Laimer, PD MD 0043(0)512504 ext 81411 Markus.Laimer@uki.at Contact: Christoph Ebenbichler, Prof MD 0043(0)512504 ext 81394 Christoh.Ebenbichler@i-med.ac.at Principal Investigator: Markus Laimer, PD MD Sub-Investigator: Christoph Ebenbichler, Prof MD Sub-Investigator: Andreas Melmer, MD PhD Sub-Investigator: Pavle Adamovski, MD 收起 << |
NCT02608905 | Type 2 Diabetes Mellitus | Phase 4 | Recruiting | May 2019 | United States, Texas ... 展开 >> Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 Contact: Mandeep Bajaj, MD 713-798-1712 bajaj@bcm.edu 收起 << |
NCT02426541 | Type 2 Diabetes Mellitus | Phase 4 | Completed | - | Finland ... 展开 >> Research Site Turku, Finland 收起 << |
NCT03180489 | Weight Loss | Phase 2 | Recruiting | May 2019 | United States, Colorado ... 展开 >> Colorado State University, Dept. of Health and Exercise Science Recruiting Fort Collins, Colorado, United States, 80523-1582 Contact: Christopher Bell, PhD 970-491-7522 Christopher.Bell@colostate.edu Contact: Laurie M Biela, BS 970-491-2242 Laurie.Biela@colostate.edu Principal Investigator: Christopher Bell, PhD Principal Investigator: Christopher Melby, Dr.P.H. 收起 << |
NCT03074630 | Diabetes Mellitus, Type 2 ... 展开 >> Hypercholesterolemia 收起 << | Phase 4 | Completed | - | Netherlands ... 展开 >> Academic Medical Center Amsterdam, North Holland, Netherlands, 1105AZ 收起 << |
NCT02981966 | Diabetes Mellitus, Type 2 | Phase 4 | Not yet recruiting | January 2021 | United States, Texas ... 展开 >> University of Texas Health Science Center San Antonio, Texas, United States, 78229 收起 << |
NCT02426541 | - | Completed | - | - | |
NCT02577159 | Diabetes Mellitus, Type 2 | Phase 4 | Active, not recruiting | August 31, 2018 | Japan ... 展开 >> Sousei Hospital Kadoma, Osaka, Japan, 5710025 Osaka Central Hospital Osaka city, Osaka, Japan, 5300001 Osaka University Hospital Suita, Osaka, Japan, 5650871 收起 << |
NCT02973477 | Type2 Diabetes ... 展开 >> Cardiovascular Diseases 收起 << | Phase 4 | Recruiting | February 2020 | United States, Michigan ... 展开 >> University of Michigan Recruiting Ann Arbor, Michigan, United States, 48104 Contact: Jacob E Reiss, B.S. 734-763-0177 jereiss@med.umich.edu Principal Investigator: Lynn Ang, M.D. Principal Investigator: Rodica Pop-Busui, M.D., Ph.D. 收起 << |
NCT03423355 | Type 2 Diabetes Mellitus (T2DM... 展开 >>) 收起 << | Phase 4 | Not yet recruiting | March 31, 2020 | Germany ... 展开 >> Technical University Dresden University Hospital Carl Gustav Carus Not yet recruiting Dresden, Germany, 01307 Contact: Andreas Birkenfeld, Prof. Dr. +49 (0) 351 458 13651 ext 13651 andreas.birkenfeld@uniklinikum-dresden.de 收起 << |
NCT02413398 | Type 2 Diabetes Mellitus | Phase 3 | Completed | - | - |
NCT02413398 | - | Completed | - | - | |
NCT02585804 | Focal Segmental Glomeruloscler... 展开 >>osis 收起 << | Phase 4 | Completed | - | Canada, Ontario ... 展开 >> Renal Physiology Laboratory, University Health Network Toronto, Ontario, Canada, M5G 2N2 收起 << |
NCT02653482 | Chronic Heart Failure With Red... 展开 >>uced Systolic Function 收起 << | Phase 4 | Recruiting | April 2019 | - |
NCT03721874 | Prediabetic State ... 展开 >> Substrate Oxidation 收起 << | Phase 4 | Not yet recruiting | January 2020 | Netherlands ... 展开 >> Maastricht University and Medical Centre Not yet recruiting Maastricht, Limburg, Netherlands, 6200 MD 收起 << |
NCT02919059 | Diabetes Mellitus, Type 2 | Phase 4 | Recruiting | August 2019 | Spain ... 展开 >> Hospital Nuestra Señora de la Esperanza Recruiting Santiago de Compostela, Galicia, Spain, 15705 Contact: Álvaro Hermida, MD, PhD 0034 981 552 200 alvaro.hermida.ameijeiras@sergas.es 收起 << |
NCT03190694 | Chronic Kidney Diseases ... 展开 >> Proteinuria 收起 << | Phase 2 | Recruiting | December 1, 2019 | Canada, British Columbia ... 展开 >> Nephrology Dept., Vancouver Coastal Health Research Institute Recruiting Vancouver, British Columbia, Canada, V5Z 1M9 Contact: Sean Barbour, MD +1-604-875-5950 Sean.Barbour@vch.ca Canada, Ontario Division of Nephrology University Health Network, University of Toronto Recruiting Toronto, Ontario, Canada, M5G 2C4 Contact: David Cherney, Prof.MD +1-416-340-4151 david.cherney@uhn.ca Malaysia Nephrology Unit, University Kebangsaan Malaysia Recruiting Kuala Lumpur, Malaysia, 5600 Contact: Halim Gafor, Prof.MD halimgafor@gmail.com University Malaya Medical Centre, Ward 8TE Recruiting Kuala Lumpur, Malaysia, 59100 Contact: Lim Soo Kun, Prof.MD 603-79494422 sookun_73@yahoo.com Netherlands Dept Internal Medicine, division of Nephrology Hospital Group Twente Not yet recruiting Almelo, Netherlands, 7609 PP Contact: Gozewijn D Laverman, MD +31-887084350 g.laverman@zgt.nl Dept.of Nephrology, VU University Medical Center Recruiting Amsterdam, Netherlands, 1081 HV Contact: Marcus G Vervloet, MD +31-9032129301 m.vervloet@vumc.nl Dept. Nephrology, University Medical Center Groningen Recruiting Groningen, Netherlands, 9713 GZ Contact: Ron T Gansevoort, MD +31-50-3616161 R.T.Gansevoort@umcg.nl 收起 << |
NCT02777073 | Type 1 Diabetes | Phase 3 | Completed | - | United States, New York ... 展开 >> ECMC Ambulatory Center, 3rd Floor Buffalo, New York, United States, 14215 收起 << |
NCT03030235 | Chronic Heart Failure With Pre... 展开 >>served Systolic Function 收起 << | Phase 4 | Recruiting | September 2019 | - |
NCT03338855 | Diabetes Mellitus, Type 2 ... 展开 >> Skeletal Muscle Insulin Sensitivity 收起 << | Phase 4 | Recruiting | December 16, 2019 | Netherlands ... 展开 >> Research Site Recruiting Maastricht, Netherlands, 6229 HX 收起 << |
NCT03619213 | Heart Failure With Preserved E... 展开 >>jection Fraction 收起 << | Phase 3 | Recruiting | June 22, 2021 | - |
NCT03537131 | Diabetes Mellitus, Type 1 | Phase 2 | Recruiting | December 22, 2018 | United Kingdom ... 展开 >> Clinical Research Unit, OCDEM, Churchill Hospital Recruiting Oxford, Oxfordshire, United Kingdom, OX3 7LE Contact: Lia Anguelova, MD lia.anguelova@ocdem.ox.ac.uk Principal Investigator: Ioannis I Spiliotis, MD 收起 << |
NCT02528019 | Effects of the DPP-4 Inhibitor... 展开 >>s or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications 收起 << | Phase 4 | Unknown | August 2018 | Japan ... 展开 >> Kurume University Hospital Recruiting Kurume city, Japan, 830-0011 Contact: Nobuhiro Tahara, MD, PhD +81-942-31-7580 ntahara@med.kurume-u.ac.jp Contact: Sho-ichi Yamagishi, MD, PhD +81-942-31-7562 Principal Investigator: Nobuhiro Tahara, MD, PhD 收起 << |
NCT02857764 | - | Completed | - | - | |
NCT03249506 | - | Completed | - | United States, Pennsylvania ... 展开 >> Health ResearchTx, LLC Trevose, Pennsylvania, United States, 19053 收起 << | |
NCT03492580 | - | Completed | - | United States, New Jersey ... 展开 >> Janssen Investigative Site Titusville, New Jersey, United States, 08560 收起 << | |
NCT02597049 | Type 2 Diabetes Mellitus | Phase 3 | Completed | - | - |
NCT02597049 | - | Completed | - | - | |
NCT02636192 | - | Completed | - | - | |
NCT03601910 | Type II Diabetes Mellitus | Phase 1 | Active, not recruiting | November 9, 2018 | Korea, Republic of ... 展开 >> The Catholic University of Korea, Seoul ST. Mary's Hospital Seoul, Korea, Republic of 收起 << |
NCT02561130 | Type 2 Diabetes Mellitus | Phase 4 | Active, not recruiting | October 2018 | Canada, Alberta ... 展开 >> University of Calgary Calgary, Alberta, Canada, T2T 5C7 Canada, Manitoba Health Science Centre Winnipeg, Manitoba, Canada, R3E 3P4 Canada, Ontario McMaster University Hamilton, Ontario, Canada, L8N 3Z5 St. Joseph's Hospital London, Ontario, Canada, N6A 4V2 Western University London, Ontario, Canada, N6G 2M1 LMC Toronto, Ontario, Canada, M4G 3E8 St. Michaels's Hospital Toronto, Ontario, Canada, M5C 2T2 收起 << |
NCT02696941 | Non-alcoholic Fatty Liver Dise... 展开 >>ase 收起 << | Phase 1 | Completed | - | United Kingdom ... 展开 >> University of Oxford Oxford, United Kingdom 收起 << |
NCT03364985 | Healthy | Phase 1 | Recruiting | December 2018 | Korea, Republic of ... 展开 >> Seoul National University Hospital Recruiting Seoul, Korea, Republic of Contact: Kyung-Sang Yu, MD, PhD 82-2-2072-1920 ksyu@snu.ac.kr 收起 << |
NCT02879409 | Diabetes Mellitus Type 2 | Not Applicable | Recruiting | August 2019 | Qatar ... 展开 >> Hamad Medical Corporation Recruiting Doha, Qatar, 3050 Contact: Ibrahim Janahi, MD 4439-2434 ext 00974 Imohd@hamad.qa Principal Investigator: Ibrahim Janahi, MD Sub-Investigator: Mashhood Siddique, MD Sub-Investigator: Hamda Ali, MD 收起 << |
NCT03209089 | - | Active, not recruiting | December 16, 2018 | Russian Federation ... 展开 >> Research Site Belgorod Region, Shebekino, Russian Federation, D1690R00037 Research Site Belgorod Region, Volokonovsky R-n, P. Volokonovka, Russian Federation, D1690R00037 Research Site Gis-Khrustalny, Russian Federation, D1690R00037 Research Site Izhevsk, Russian Federation, D1690R00037 Research Site Kazan, Russian Federation, D1690R00037 Research Site Lipetsk, Russian Federation, D1690R00037 Research Site N. Novgorod Region, Russian Federation, D1690R00037 Research Site N. Novgorod, Russian Federation, D1690R00037 Research Site Novomoskovsk, Russian Federation, D1690R00037 Research Site Novosibirsk, Russian Federation, D1690R00037 Research Site Perm, Russian Federation, D1690R00037 Research Site Ryazan, Russian Federation, D1690R00037 Research Site Samara, Russian Federation, D1690R00037 Research Site St-petersburg, Russian Federation, D1690R00037 Research Site Tambov Region, Russian Federation, D1690R00037 Research Site Volzhsk, Russian Federation, D1690R00037 Research Site Voronezh Region, Novovoronezh, Russian Federation, D1690R00037 Research Site Voronezh, Russian Federation, D1690R00037 Research Site Yaroslavl, Russian Federation, D1690R00037 Research Site Yoshkar-Ola, Russian Federation, D1690R00037 收起 << | |
NCT03646799 | Type II Diabetes | Phase 1 | Recruiting | September 14, 2018 | Korea, Republic of ... 展开 >> Yonsei University Severance Hospital Recruiting Soeul, Korea, Republic of Contact: Min Soo Park, Ph.D. M.D +82 2 2228 0400 minspark@yuhs.ac Principal Investigator: Min Soo Park, Ph.D. M.D 收起 << |
NCT03627039 | - | Not yet recruiting | August 1, 2020 | - | |
NCT03038789 | - | Recruiting | January 31, 2020 | Korea, Republic of ... 展开 >> Research Site Recruiting Busan, Korea, Republic of Research Site Recruiting ChungCheong, Korea, Republic of Research Site Recruiting DaeGu, Korea, Republic of Research Site Recruiting DaeJeon, Korea, Republic of Research Site Recruiting GyeongGi, Korea, Republic of Research Site Active, not recruiting GyeongGi, Korea, Republic of Research Site Recruiting Seoul, Korea, Republic of Research Site Withdrawn Seoul, Korea, Republic of Research Site Recruiting WonJu, Korea, Republic of 收起 << | |
NCT02969798 | Diabetes Mellitus, Type 2 ... 展开 >> Impaired Glucose Tolerance (IGT) Impaired Fasting Glucose (IFG) 收起 << | Not Applicable | Recruiting | July 2020 | United States, Texas ... 展开 >> The University of Texas Health Science Center at San Antonio Recruiting San Antonio, Texas, United States, 78229 Contact: Ralph A DeFronzo, MD 210-567-6691 defronzo@uthscsa.edu Contact: Monica Palomo, BS 210-567-6710 palomom@uthscsa.edu Principal Investigator: Ralph A DeFronzo, MD Sub-Investigator: Eugenio Cersosimo, MD 收起 << |
NCT02252224 | - | Completed | - | Korea, Republic of ... 展开 >> Research Site Bucheon-si, Korea, Republic of Research Site Busan, Korea, Republic of Research Site Daejeon, Korea, Republic of Research Site Jeonju-si, Korea, Republic of Research Site Seoul, Korea, Republic of Research Site Wonju-si, Korea, Republic of 收起 << | |
NCT02695173 | - | Recruiting | November 30, 2019 | United States, Delaware ... 展开 >> Research Site Recruiting Wilmington, Delaware, United States United States, District of Columbia Research Site Recruiting Washington, District of Columbia, United States United Kingdom Research Site Recruiting London, United Kingdom 收起 << | |
NCT02695082 | - | Recruiting | November 30, 2019 | United States, Delaware ... 展开 >> Research Site Recruiting Wilmington, Delaware, United States United States, District of Columbia Research Site Recruiting Washington, District of Columbia, United States United Kingdom Research Site Recruiting London, United Kingdom 收起 << | |
NCT03422263 | - | Recruiting | December 31, 2019 | Switzerland ... 展开 >> Berner Klinik Montana Recruiting Crans-Montana, Valais, Switzerland, 3963 Contact: Devine S Frundi, MD +41 274855242 devine.frundi@bernerklinik.ch 收起 << |
尊敬的 Ambeed 客户您好,
请您选择所在区域,我们将转接对应客服为您服务!